AMLX

#1890
Amylyx Pharmaceuticals, Inc. Common Stock
15.17
+1.68%
セクター:
ベース:
利益通貨:
日中レンジ
15.17
15.17
1年のレンジ
2.60
17.49
1日の変化
+1.68%
月次変化
-2.00%
6か月変化
+60.53%
1年の変化
+384.66%
以前の終値
14.92
Open
15.17
Bid
Ask
Low
15.17
High
15.17
ボリューム
174
Open full chart

Financials

Overview 明細書 Statistics Dividends
Quarterly Annual
Value 202220232024 TTM
Key stats
Valuation ratios
Profitability ratios
Liquidity ratios
Solvency ratios
Per share metrics

Amylyx Pharmaceuticals Inc

Amylyx Pharmaceuticals, Inc is a biopharmaceutical company headquartered in Cambridge, Massachusetts. Amylyx is best known for AMX0035, an experimental therapy for amyotrophic lateral sclerosis. AMX0035 was approved for medical use in Canada as Albrioza, in June 2022, and in the United States, as Relyvrio, in September 2022. It was withdrawn in April, 2024.

ニュース